Literature DB >> 19734762

Risk factors for second eye progression to advanced age-related macular degeneration: SST report No. 21 Submacular Surgery Trials Research Group.

Sharon D Solomon, Joan L Jefferys, Barbara S Hawkins, Neil M Bressler, Susan B Bressler.   

Abstract

OBJECTIVE: To identify characteristics predictive of progression to advanced age-related macular degeneration (AMD) in second (fellow) eyes of participants in the Submacular Surgery Trials (SST) who had unilateral neovascular AMD at study entry.
METHODS: Review of baseline fluorescein angiograms confirmed the absence of advanced AMD in 370 fellow eyes. All participants were eligible for 2 years of follow-up; follow-up angiograms of eyes at risk were evaluated to estimate incidence rates of advanced AMD. Baseline nonocular and ocular AMD characteristics were evaluated to identify those that predicted development of advanced AMD.
RESULTS: Of 110 eyes that progressed to advanced AMD, choroidal neovascularization (CNV) developed in 98 eyes and foveal geographic atrophy (GA) in 15 eyes. No nonocular characteristic (age, gender, history of hypertension or smoking) or ocular feature of the study eye at baseline (lesion composition, lesion size, or visual acuity) was predictive of progression to advanced AMD in this cohort. Multivariate analysis identified three baseline fellow eye ocular features that had a significant and independent relationship with progression to advanced AMD: drusen size, focal hyperpigmentation, and nonfoveal GA.
CONCLUSION: Recognition of factors that predict advanced AMD in the second eye may identify those individuals at greater risk of progression so that treatment can be provided before vision is severely compromised.

Entities:  

Mesh:

Year:  2009        PMID: 19734762     DOI: 10.1097/IAE.0b013e3181b1baeb

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  7 in total

1.  Short- and mid-term repeatability of macular pigment optical density measurements using spectral fundus reflectance.

Authors:  Nikolaus Dragostinoff; René Marcel Werkmeister; Semira Kaya; Günther Weigert; Berthold Pemp; Stefan Sacu; Gerhard Garhöfer; Ursula Schmidt-Erfurth; Leopold Schmetterer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-02-25       Impact factor: 3.117

2.  Incidence and risk factors for neovascular age-related macular degeneration in the fellow eye.

Authors:  Toke Bek; Sidsel Ehlers Klug
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-10       Impact factor: 3.117

3.  Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.

Authors:  Frank G Holz; Srinivas R Sadda; Brandon Busbee; Emily Y Chew; Paul Mitchell; Adnan Tufail; Christopher Brittain; Daniela Ferrara; Sarah Gray; Lee Honigberg; Jillian Martin; Barbara Tong; Jason S Ehrlich; Neil M Bressler
Journal:  JAMA Ophthalmol       Date:  2018-06-01       Impact factor: 7.389

4.  Optical coherence tomography changes before the development of choroidal neovascularization in second eyes of patients with bilateral wet macular degeneration.

Authors:  K N Amissah-Arthur; S Panneerselvam; N Narendran; Y C Yang
Journal:  Eye (Lond)       Date:  2011-12-23       Impact factor: 3.775

5.  Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial.

Authors:  Ebenezer Daniel; Maureen G Maguire; Juan E Grunwald; Cynthia A Toth; Glenn J Jaffe; Daniel F Martin; Gui-Shuang Ying
Journal:  JAMA Ophthalmol       Date:  2020-05-01       Impact factor: 7.389

6.  Geographic atrophy: a histopathological assessment.

Authors:  Alan C Bird; Rachel L Phillips; Gregory S Hageman
Journal:  JAMA Ophthalmol       Date:  2014-03       Impact factor: 7.389

7.  Low incidence of choroidal neovascularization following subthreshold diode micropulse laser (SDM) in high-risk AMD.

Authors:  Jeffrey K Luttrull; Stephen H Sinclair; Solly Elmann; Bert M Glaser
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.